Pluri Inc.
- PLUR
- NASDAQ
- Biotechnology
- Cell Therapy (Placenta-derived)
- Regenerative Medicine
$0.85
Today −8.58%Quote Oct 19, 2026, 08:00 PM UTC
−21.29%over the last month
Max drawdown −22.7%From 1-month high −22.7%3 months −56.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Pluri
Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
92
Market value
$10.5M
Quote Oct 19
Analyst target
$12.00
+1311.6% from here
Floor
$0.85
0.0% below price
Resistance
$0.87
2.2% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about PLURPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free